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Objectives
To analyse differences in survival between patients pre-
senting community acquired advanced acute kidney
injury (CAKIN3) and hospital acquired advanced acute
kidney injury (HAKIN3). We also evaluated Renal
Replacement Therapy (RRT) timing impact in these two
populations.
Methods
We studied a cohort of 217 critically ill patients all of
them presenting advanced acute kidney injury (AKIN3)
at some point of their hospital stay. Patients with pre-
vious advanced chronic kidney disease (CKD5) were
excluded. CAKIN3 was defined as those patients who
presented AKIN3 at hospital admission and HAKIN3
was defined as those patients who presented no AKI at
hospital admission. Both groups studied presented
AKIN3 within the first 24h of ICU admission. To evalu-
ate RRT timing impact we defined as Early RRT those
patients whom were initiated on RRT within the first
48 hours from hospital admission (CAKIN3) or within
the first 48 hours from ICU admission (HAKIN3).
Patients with more than 7 days from hospital admission
(CAKIN3) or ICU admission (KAKIN3) to RRT initia-
tion were both excluded from RRT timing analysis. Non
RRT control group was also included in timing analysis.
Results
90 days mortality was 51.5% in CAKIN3 patients and
71.1 % in HAKIN3 patients (p = 0.005). RRT was
required in 82.8% of CAKIN3 patients vs 89.2% of
HAKIN3 patients.
No differences between CAKIN3 and HAKIN3 were
observed in terms of age (62 ± 15 vs 61 ± 14 years), SOFA
score (12 ± 4 vs 12 ± 4), baseline creatinine (100 ± 46 vs
108 ± 50 umol/L), Lactate at ICU admission (6.2 ± 7 vs
5.2 ± 5.5 mmol/L), days from ICU to RRT (2.5 ± 6.8 vs
1.5 ± 1.8 days), urine output at RRT initiation (0.25 ± 0.34
vs 0.20 ± 0.23 ml/kg/h), mechanical ventilation at RRT
initiation (81% vs 79%), or presence of shock at RRT initia-
tion (94.6% vs 90.2%).
Differences between CAKIN3 and HAKIN3 were
observed in terms of creatinine at hospital admission
(379 ± 268 vs 108 ± 54 umol/L), creatinine at ICU
admission (372 ± 225 vs 260 ± 134 umol/L), urine out-
put within the first 24h of ICU admission (0.40 ± 0.49
vs 0.28 ± 0.30 ml/kg/h), creatinine at RRT initiation
(435 ± 205 vs 337 ± 128 umol/L), pH at RRT initiation
(7.25 ± 0.13 vs 7.29 ± 0.11), diabetes mellitus (31.5% vs
19%), and Chronic obstructive pulmonary disease-COPD
(23.1% vs 9.6%). Most of CAKIN3 patients were medical
(60.3%) and most of HAKIN3 patients were surgical
(58.3%).
In CAKIN3 patients Early RRT improved 90 day sur-
vival compared to Late RRT and non RRT patients (p =
0.049). In HAKIN3 patients Early RRT had no survival
impact compared to Late RRT or non-RRT patients.
Conclusions
Community acquired advanced AKI seems to present
better outcome respect to hospital acquired advanced
AKI. Early RRT seems to improve outcome in commu-
nity acquired advanced AKI but has no beneficial impact
on hospital acquired advanced AKI.
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